{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2
  ],
  "modelUsed": "gemini-3-flash-preview",
  "metadata": {
    "studyName": "A PHASE III, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI–P",
    "titles": [
      {
        "id": "title_1",
        "text": "A PHASE III, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI–PD-L1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER",
        "type": {
          "code": "Official Study Title",
          "codeSystem": "USDM",
          "decode": "Official Study Title"
        },
        "instanceType": "StudyTitle"
      },
      {
        "id": "title_2",
        "text": "IMpassion131",
        "type": {
          "code": "Study Acronym",
          "codeSystem": "USDM",
          "decode": "Study Acronym"
        },
        "instanceType": "StudyTitle"
      }
    ],
    "identifiers": [
      {
        "id": "sid_1",
        "text": "NCT03125902",
        "scopeId": "org_ct_gov",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "NCT",
          "codeSystem": "USDM",
          "decode": "ClinicalTrials.gov Identifier"
        }
      },
      {
        "id": "sid_2",
        "text": "MO39196",
        "scopeId": "org_1",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "SponsorProtocolNumber",
          "codeSystem": "USDM",
          "decode": "Sponsor Protocol Number"
        }
      },
      {
        "id": "sid_3",
        "text": "2016-004024-29",
        "scopeId": "org_eudract",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "EudraCT",
          "codeSystem": "USDM",
          "decode": "EudraCT Number"
        }
      },
      {
        "id": "sid_4",
        "text": "123277",
        "scopeId": "org_unknown",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "IND",
          "codeSystem": "USDM",
          "decode": "FDA IND Number"
        }
      }
    ],
    "organizations": [
      {
        "id": "org_1",
        "name": "F. Hoffmann-La Roche Ltd",
        "type": {
          "id": "41b62f00-2bdb-45af-a922-0cc5b32bbb56",
          "code": "C54086",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Pharmaceutical Company",
          "instanceType": "Code"
        },
        "identifier": "F. Hoffmann-La Roche Ltd",
        "identifierScheme": "DUNS",
        "instanceType": "Organization"
      },
      {
        "id": "org_2",
        "name": "Genentech, Inc.",
        "type": {
          "id": "cb8328ff-4ef8-4643-b9f5-ec275b68a3db",
          "code": "C54086",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Pharmaceutical Company",
          "instanceType": "Code"
        },
        "identifier": "Genentech, Inc.",
        "identifierScheme": "DUNS",
        "instanceType": "Organization"
      },
      {
        "id": "org_3",
        "name": "French National Agency for the Safety of Medicines and Health Products (ANSM)",
        "type": {
          "id": "a73cdfb0-7087-44f4-baa5-9e5d3742840b",
          "code": "C25461",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Regulatory Agency",
          "instanceType": "Code"
        },
        "identifier": "French National Agency for the Safety of Medicines and Health Products (ANSM)",
        "identifierScheme": "DUNS",
        "instanceType": "Organization"
      }
    ],
    "roles": [
      {
        "id": "role_1",
        "name": "Sponsor",
        "code": {
          "code": "Sponsor",
          "codeSystem": "USDM",
          "decode": "Sponsor"
        },
        "organizationIds": [
          "org_1"
        ],
        "instanceType": "StudyRole"
      },
      {
        "id": "role_2",
        "name": "Local Affiliate",
        "code": {
          "code": "Sponsor",
          "codeSystem": "USDM",
          "decode": "Sponsor"
        },
        "organizationIds": [
          "org_2"
        ],
        "instanceType": "StudyRole"
      },
      {
        "id": "role_3",
        "name": "Regulatory Authority",
        "code": {
          "code": "Regulatory Agency",
          "codeSystem": "USDM",
          "decode": "Regulatory Agency"
        },
        "organizationIds": [
          "org_3"
        ],
        "instanceType": "StudyRole"
      }
    ],
    "indications": [
      {
        "id": "ind_1",
        "name": "Triple-Negative Breast Cancer",
        "isRareDisease": false,
        "instanceType": "Indication",
        "description": "Previously untreated inoperable locally advanced or metastatic triple-negative breast cancer"
      }
    ],
    "studyPhase": {
      "code": "Phase3",
      "codeSystem": "USDM",
      "decode": "Phase3"
    },
    "studyType": "Interventional"
  },
  "rawResponse": {
    "titles": [
      {
        "id": "title_1",
        "text": "A PHASE III, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI–PD-L1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER",
        "type": {
          "code": "OfficialStudyTitle",
          "codeSystem": "http://www.cdisc.org/USDM/titleType",
          "decode": "Official Study Title"
        },
        "instanceType": "StudyTitle"
      },
      {
        "id": "title_2",
        "text": "IMpassion131",
        "type": {
          "code": "StudyAcronym",
          "codeSystem": "http://www.cdisc.org/USDM/titleType",
          "decode": "Study Acronym"
        },
        "instanceType": "StudyTitle"
      }
    ],
    "identifiers": [
      {
        "id": "sid_1",
        "text": "NCT03125902",
        "identifierType": "NCT",
        "issuingOrganization": "ClinicalTrials.gov",
        "instanceType": "StudyIdentifier"
      },
      {
        "id": "sid_2",
        "text": "MO39196",
        "identifierType": "SponsorProtocolNumber",
        "issuingOrganization": "F. Hoffmann-La Roche Ltd",
        "instanceType": "StudyIdentifier"
      },
      {
        "id": "sid_3",
        "text": "2016-004024-29",
        "identifierType": "EudraCT",
        "issuingOrganization": "EudraCT",
        "instanceType": "StudyIdentifier"
      },
      {
        "id": "sid_4",
        "text": "123277",
        "identifierType": "IND",
        "issuingOrganization": "FDA",
        "instanceType": "StudyIdentifier"
      }
    ],
    "organizations": [
      {
        "id": "org_1",
        "name": "F. Hoffmann-La Roche Ltd",
        "type": {
          "code": "Sponsor",
          "codeSystem": "http://www.cdisc.org/USDM/organizationType",
          "decode": "Sponsor"
        },
        "role": "Sponsor",
        "instanceType": "Organization"
      },
      {
        "id": "org_2",
        "name": "Genentech, Inc.",
        "type": {
          "code": "Sponsor",
          "codeSystem": "http://www.cdisc.org/USDM/organizationType",
          "decode": "Sponsor"
        },
        "role": "Local Affiliate",
        "instanceType": "Organization"
      },
      {
        "id": "org_3",
        "name": "French National Agency for the Safety of Medicines and Health Products (ANSM)",
        "type": {
          "code": "RegulatoryAuthority",
          "codeSystem": "http://www.cdisc.org/USDM/organizationType",
          "decode": "Regulatory Authority"
        },
        "role": "Regulatory Authority",
        "instanceType": "Organization"
      }
    ],
    "studyPhase": {
      "code": "Phase3",
      "codeSystem": "http://www.cdisc.org/USDM/studyPhase",
      "decode": "Phase 3"
    },
    "studyType": "Interventional",
    "indication": {
      "id": "ind_1",
      "name": "Triple-Negative Breast Cancer",
      "description": "Previously untreated inoperable locally advanced or metastatic triple-negative breast cancer",
      "instanceType": "Indication"
    }
  }
}